Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?
Publication
, Journal Article
Goyal, A; Blazing, M
Published in: Am Heart J
October 2005
Duke Scholars
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
October 2005
Volume
150
Issue
4
Start / End Page
650 / 651
Location
United States
Related Subject Headings
- Risk Factors
- Middle Aged
- Male
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Evidence-Based Medicine
- Coronary Disease
- Cardiovascular System & Hematology
- C-Reactive Protein
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Goyal, A., & Blazing, M. (2005). Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? Am Heart J, 150(4), 650–651. https://doi.org/10.1016/j.ahj.2005.08.001
Goyal, Abhinav, and Michael Blazing. “Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?” Am Heart J 150, no. 4 (October 2005): 650–51. https://doi.org/10.1016/j.ahj.2005.08.001.
Goyal A, Blazing M. Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? Am Heart J. 2005 Oct;150(4):650–1.
Goyal, Abhinav, and Michael Blazing. “Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?” Am Heart J, vol. 150, no. 4, Oct. 2005, pp. 650–51. Pubmed, doi:10.1016/j.ahj.2005.08.001.
Goyal A, Blazing M. Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event? Am Heart J. 2005 Oct;150(4):650–651.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
October 2005
Volume
150
Issue
4
Start / End Page
650 / 651
Location
United States
Related Subject Headings
- Risk Factors
- Middle Aged
- Male
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Humans
- Evidence-Based Medicine
- Coronary Disease
- Cardiovascular System & Hematology
- C-Reactive Protein
- 3201 Cardiovascular medicine and haematology